Titan Pharmaceuticals Statistics
Total Valuation
TTNP has a market cap or net worth of $3.60 million. The enterprise value is $771,082.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TTNP has 914,234 shares outstanding. The number of shares has increased by 19.55% in one year.
| Current Share Class | 914,234 |
| Shares Outstanding | 914,234 |
| Shares Change (YoY) | +19.55% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 23.43% |
| Owned by Institutions (%) | 1.47% |
| Float | 700,056 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.05
| Current Ratio | 6.05 |
| Quick Ratio | 5.99 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -103.63% and return on invested capital (ROIC) is -59.05%.
| Return on Equity (ROE) | -103.63% |
| Return on Assets (ROA) | -51.74% |
| Return on Invested Capital (ROIC) | -59.05% |
| Return on Capital Employed (ROCE) | -186.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.18M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.93% in the last 52 weeks. The beta is 1.28, so TTNP's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -46.93% |
| 50-Day Moving Average | 3.67 |
| 200-Day Moving Average | 4.60 |
| Relative Strength Index (RSI) | 51.72 |
| Average Volume (20 Days) | 36,099 |
Short Selling Information
The latest short interest is 9,547, so 1.04% of the outstanding shares have been sold short.
| Short Interest | 9,547 |
| Short Previous Month | 12,810 |
| Short % of Shares Out | 1.04% |
| Short % of Float | 1.36% |
| Short Ratio (days to cover) | 1.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.56M |
| Pretax Income | -4.95M |
| Net Income | -4.71M |
| EBITDA | -4.55M |
| EBIT | -4.56M |
| Earnings Per Share (EPS) | -$5.23 |
Full Income StatementBalance Sheet
The company has $2.83 million in cash and n/a in debt, giving a net cash position of $2.83 million or $3.10 per share.
| Cash & Cash Equivalents | 2.83M |
| Total Debt | n/a |
| Net Cash | 2.83M |
| Net Cash Per Share | $3.10 |
| Equity (Book Value) | 2.44M |
| Book Value Per Share | 2.67 |
| Working Capital | 2.44M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.88M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.88M |
| FCF Per Share | -$4.24 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |